# VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

> **NCT04166383** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Colorectal Neoplasms
- Colorectal Carcinoma
- Colorectal Cancer With Hepatic Metastases
- Colorectal Tumors

## Interventions

- **BIOLOGICAL:** Vascular Biogenics (VB)-111
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04166383
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-09
- **Primary completion:** 2022-04-12
- **Final completion:** 2022-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Interim analysis indicated limited efficacy
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166383, "VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04166383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*